Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
Item 5.07. Submission of Matters to a Vote of Security Holders.
The following is a brief description of each proposal voted upon at the Annual
Meeting and the final voting results for each such proposal. As of the record
date for the Annual Meeting,
Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years. The results of the vote were as follows: Name of Nominee For Against Abstain Broker Non- Votes Kathryn Boor, Ph.D. 67,109,976 134,940 27,270 7,791,989 Michael Chambers 67,104,537 138,475 29,174 7,791,989 Douglas S. Ingram 66,697,111 546,004 29,071 7,791,989
Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2021. The results of the advisory vote were as follows:
For Against Abstain Broker Non-Votes 62,746,933 4,465,735 59,518 7,791,989
Proposal 3: Amendment to the Company's 2018 Equity Incentive Plan The stockholders approved the 2018 Plan Amendment. The results of the vote were as follows:
For Against Abstain Broker Non-Votes 62,644,364 4,572,292 55,530 7,791,989
Proposal 4: Ratification of
For Against Abstain 73,729,807 1,244,784 89,584
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
--------------------------------------------------------------------------------
Exhibit Number Description Amendment No. 2 to theSarepta Therapeutics, Inc. 2018 Equity 10.1 Incentive Plan The cover page from this Current Report on Form 8-K of Sarepta 104Therapeutics, Inc. , formatted in Inline XBRL and included as Exhibit 101
--------------------------------------------------------------------------------
© Edgar Online, source